Ethypharm expands its Mesalazine (Etiasa®) Portfolio in China

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ethypharm-Mesalazine

More Like This

Dr. Aron Blaesi, inventor of expandable, gastroretentive fibrous dosage forms presenting dosage forms before and after expansion due to water absorption. (Photo: Business Wire)

Enzian Pharmaceutics Develops a Novel Dosage Form for Enhanced Efficacy and Reduced Side Effects of Cancer Therapies

e-therapeutics Presents New Data Supporting ETX‑312 as a Differentiated and Disease-Modifying Near-Clinic Treatment for MASH

PR Newswire associated0

ACQUISITION OF ARGATROBAN BUSINESS IN EUROPE

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA® (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease

Enteralia Bioscience SRL Acquires TFarma SRL

PR Newswire associated0

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

PR Newswire associated0

Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension

Samsung Bioepis office in Songdo, Incheon, Republic of Korea

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates